dc.contributor.author | Holien, Toril | |
dc.contributor.author | Misund, Kristine | |
dc.contributor.author | Olsen, Oddrun Elise | |
dc.contributor.author | Baranowska, Katarzyna Anna | |
dc.contributor.author | Buene, Glenn | |
dc.contributor.author | Børset, Magne | |
dc.contributor.author | Waage, Anders | |
dc.contributor.author | Sundan, Anders | |
dc.date.accessioned | 2015-06-03T20:47:43Z | |
dc.date.accessioned | 2015-06-08T10:57:25Z | |
dc.date.available | 2015-06-03T20:47:43Z | |
dc.date.available | 2015-06-08T10:57:25Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | OncoTarget 2015 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.uri | http://hdl.handle.net/11250/284777 | |
dc.description.abstract | In multiple myeloma, elevated MYC expression is related to disease initiation
and progression. We found that in myeloma cell lines, MYC gene amplifications were
common and correlated with MYC mRNA and protein. In primary cell samples MYC
mRNA levels were also relatively high; however gene copy number alterations were
uncommon. Elevated levels of MYC in primary myeloma cells have been reported
to arise from complex genetic aberrations and are more common than previously
thought. Thus, elevated MYC expression is achieved differently in myeloma cell lines
and primary cells. Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4
correlated with MYC expression, supporting that the activity of 10058-F4 was through
specific inhibition of MYC. | |
dc.language.iso | eng | |
dc.title | MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy | |
dc.type | Journal article | |
dc.type | Peer reviewed | en_GB |
dc.date.updated | 2015-06-03T20:47:42Z | |
dc.source.journal | OncoTarget | |
dc.identifier.doi | 10.18632/oncotarget.4245 | |
dc.identifier.cristin | 1246200 | |
dc.description.localcode | Copyright @ 2008-2015 Impact Journals, LLC. All rights reserved.
Impact Journals is a trademark of Impact Journals, LLC . All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. | |